A potent tumor-selective ERK pathway inactivator with high therapeutic index

FDA-approved BRAF and MEK small molecule inhibitors have demonstrated some level of efficacy in patients with metastatic melanomas. However, these “targeted” therapeutics have a very low therapeutic index, since these agents affect normal cells, causing undesirable, even fatal, side effects. To addr...

Descripción completa

Detalles Bibliográficos
Autores principales: Zuo, Zehua, Liu, Jie, Sun, Zhihao, Silverstein, Rachel, Zou, Meijuan, Finkel, Toren, Bugge, Thomas H, Leppla, Stephen H, Liu, Shihui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Biological, Health, and Medical Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308561/
https://www.ncbi.nlm.nih.gov/pubmed/35899070
http://dx.doi.org/10.1093/pnasnexus/pgac104

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308561/
https://www.ncbi.nlm.nih.gov/pubmed/35899070
http://dx.doi.org/10.1093/pnasnexus/pgac104

Ejemplares similares